ENGLEWOOD CLIFFS, NJ / ACCESSWIRE / December 11, 2017 / Immune Pharmaceuticals Inc. (NASDAQ: IMNP) (the "Company"), a biopharmaceutical company developing novel therapeutic agents for the ...

ENGLEWOOD CLIFFS, NJ / ACCESSWIRE / December 11, 2017 / Immune Pharmaceuticals Inc. (NASDAQ: IMNP) (the "Company"), a biopharmaceutical company developing novel therapeutic agents for the treatment of ...

The doctor, John Zhang, used the technique to help a Jordanian couple have a baby boy last year. According to the Food and Drug Administration, Zhang said his companies wouldn’t use the ...

Last fall, John Zhang made headlines after his fertility clinic announced that for the first time a baby had been born using a new technique requiring. Skip to content Gizmodo. Search .

John Zhang produced a three-parent baby, implanted abnormal embryos and wants to help 60-year-old women have children.

Zhang says Darwin Life will charge $80,000 to $120,000 for spindle nuclear transfer. He estimates there is a market worth $2 billion per year considering how many women can’t conceive because of ...

John Zhang, once labeled a “fertility rebel” for creating an embryo with DNA from three parents, says former employee Dr. Mingxue Yang has been acting like a rotten egg, according to a ...

Last year, John Zhang, the founder of New Hope Fertility Center, pioneered a new type of… The agency is taking a hard line on a controversial fertility technique that involves genetically ...

The health watchdog published a letter to Dr. John Zhang, founder of the New Hope Fertility Center in New York City, whose “spindle nuclear transfer” technique was used to conceive a boy born ...

Dr. John Zhang is offering women in their 40s a “solution” for age-related infertility — swapping chromosomes between two women’s eggs, resulting in a child with, ...

A doctor who treats infertility in New York City says he has helped a couple have the first baby purposefully created with DNA from three different adults. John Zhang of the New Hope Fertility ...

ENGLEWOOD CLIFFS, NJ / ACCESSWIRE / December 11, 2017 / Immune Pharmaceuticals Inc. (NASDAQ: IMNP) (the "Company"), a biopharmaceutical company developing novel therapeutic agents for the treatment of ...